ADP-A2M4

Overview

Overview

Our ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types. The MAGE- A4 antigen is among the most commonly expressed cancer-testis antigens. We are conducting various trials with the ADP-A2M4 SPEAR T-cell in various solid tumors.

Our Trials

Target Trial Indications Phase 1 Phase 2/3
MAGE-A4 SPEARHEAD‑1 (ADP‑A2M4) Synovial Sarcoma MRCLS
Phase 1 Phase complete
Phase 2/3 Phase in progress
Phase 1 trial (ADP‑A2M4) Multiple solid tumors** info
Phase 1 Phase in progress
Phase 2/3 Phase not started
Radiation sub‑study* (ADP‑A2M4) Multiple solid tumors**
Phase 1 Phase in progress
Phase 2/3 Phase not started

*Site specific protocol amendment with MD Anderson Cancer Center

**Bladder, Melanoma, Head & Neck, Ovarian, NSCLC, Esophageal, Gastric, Synovial sarcoma, MRCLS

Cancer indications in the ADP-A2M4 trial

Urothelial

Urothelial

Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is the most common type of bladder cancer.

Melanoma

Melanoma

Melanoma is a cancer that begins in specific skin cells called melanocytes.

Head and Neck

Head and Neck

Head and neck cancer arises in the epithelium of the paranasal sinuses, nasopharynx, oropharynx, oral cavity, hypopharynx and larynx.

Ovarian

Ovarian

Ovarian cancer begins in the ovaries, which are made up of 3 main kinds of cells. Each type of cell can develop into a different type of tumor.

Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer or NSCLC is the most common type of lung cancer, representing about 85% of lung cancers.

Gastric

Gastric

Stomach cancers, or gastric cancers, tend to develop slowly over many years.

Synovial Sarcoma

Synovial Sarcoma

Soft tissue sarcomas can develop from soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.

Myxoid/Round Cell Liposarcoma (MRCLS)

Myxoid/Round Cell Liposarcoma (MRCLS)

Soft tissue sarcomas can develop from soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.

Publications

Review our findings and publications.

Latest News

On November 16, 2019, we presented updated data from people with synovial sarcoma treated in the ongoing Phase 1 trial with ADP-A2M4. Out of the 14 patients with synovial sarcoma who have been treated in the expansion phase of this trial and have post-baseline scans, to date, seven have had clinical responses (including both confirmed and unconfirmed partial responses [PRs] by RECIST criteria) representing an overall response rate of 50%. Thirteen patients showed clinical benefit with best overall responses of PR (confirmed or unconfirmed; n=7) or stable disease (SD; n=6) – representing a disease control rate of 93%.

View Press Release